Oxford BioMedica plc Company Profile (LON:OXB)

About Oxford BioMedica plc

Oxford BioMedica plc logoOxford BioMedica plc is a United Kingdom-based gene and cell therapy research and development business. The Company is lentiviral vector and cell therapy research, development and manufacture. It provides a platform of technologies and capabilities with which it designs, develops and manufactures gene and cell-based medicines. The Company's clinical pipeline is targeting Parkinson's disease, selected cancers and a number of serious eye diseases. The Company has four clinical programs in active development and two other products, including EncorStat and OXB-102, being readied for Phase I/II. EncorStat is being studied for the prevention of corneal graft rejection. OXB-102 is being studied to target Parkinson's disease.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: OXB
  • CUSIP:
Key Metrics:
  • Previous Close: $0.06
  • 50 Day Moving Average: $4.24
  • 200 Day Moving Average: $5.39
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $106.86M
  • Outstanding Shares: 2,568,645,000
Additional Links:

Analyst Ratings

Consensus Ratings for Oxford BioMedica plc (LON:OXB) (?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: GBX 6

Analysts' Ratings History for Oxford BioMedica plc (LON:OXB)
DateFirmActionRatingPrice TargetDetails
3/7/2016N+1 SingerReiterated RatingSellGBX 6View Rating Details
4/16/2015Roth CapitalReiterated RatingBuyGBX 18View Rating Details
10/10/2014Peel HuntUpgradeBuyGBX 3 -> GBX 6View Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Oxford BioMedica plc (LON:OXB)
No earnings announcements for this company have been tracked by MarketBeat.com


Earnings Estimates for Oxford BioMedica plc (LON:OXB)
Current Year EPS Consensus Estimate: $-0.52 EPS


Dividend History for Oxford BioMedica plc (LON:OXB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Oxford BioMedica plc (LON:OXB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2016Tallarigo ,LorenzoInsiderBuy62,257GBX 4£2,490.28
7/25/2016Tallarigo ,LorenzoInsiderBuy63,351GBX 4£2,534.04
6/24/2016Tallarigo ,LorenzoInsiderBuy62,847GBX 4£2,513.88
5/13/2016Diggle ,MartinInsiderBuy42,072GBX 5£2,103.60
5/12/2016Diggle ,MartinInsiderBuy45,428GBX 5£2,271.40
5/5/2016Diggle ,MartinInsiderBuy12,500GBX 6£750
5/4/2016Diggle ,MartinInsiderBuy44,689GBX 6£2,681.34
5/3/2016Diggle ,MartinInsiderBuy317,382GBX 6£19,042.92
4/29/2016Nolan,PeterInsiderBuy359,925GBX 6£21,595.50
4/22/2016Tallarigo ,LorenzoInsiderBuy41,083GBX 6£2,464.98
3/24/2016Tallarigo ,LorenzoInsiderBuy41,550GBX 6£2,493
2/26/2016Diggle ,MartinInsiderBuy29,345GBX 7£2,054.15
2/25/2016Tallarigo ,LorenzoInsiderBuy36,370GBX 7£2,545.90
2/24/2016Diggle ,MartinInsiderBuy46,693GBX 6£2,801.58
7/1/2015Diggle ,MartinInsiderBuy284,439GBX 0.09£256
6/30/2015Diggle ,MartinInsiderBuy775,000GBX 0.09£697.50
6/19/2015Diggle ,MartinInsiderBuy225,000GBX 0.08£180
6/12/2015Martin DiggleInsiderBuy283,978GBX 9.01£25,586.42
6/11/2015Martin DiggleInsiderBuy416,022GBX 9£37,441.98
6/9/2015Daniel SolandInsiderBuy500,000GBX 9.45£47,250
5/21/2015Andrew HeathInsiderBuy100,000GBX 10.60£10,600
5/19/2015Tim WattsInsiderBuy194,174GBX 10.30£19,999.92
(Data available from 1/1/2013 forward)


Latest Headlines for Oxford BioMedica plc (LON:OXB)
money.aol.co.uk logoWhy are these three shares climbing today? - AOL Money UK (LON:OXB)
money.aol.co.uk - August 15 at 7:01 PM
uk.finance.yahoo.com logoWhy are these three shares climbing today? (LON:OXB)
uk.finance.yahoo.com - August 15 at 8:53 AM
News IconFinding the cure: rare diseases - Investors Chronicle (LON:OXB)
www.investorschronicle.co.uk - August 6 at 9:30 AM
ftsenews.co.uk logoOutstanding Analyst Ratings For Oxford Biomedica (LON:OXB) - FTSE News (LON:OXB)
www.ftsenews.co.uk - August 2 at 11:39 AM
publicnow.com logoManufacturing Approvals and Expansion Completed (LON:OXB)
www.publicnow.com - July 28 at 3:28 AM
News IconOxford BioMedica plc Declines A lot Today, Is Now One of The Worst Performer - Consumer Eagle (LON:OXB)
www.consumereagle.com - July 21 at 6:59 PM
ftsenews.co.uk logoOxford Biomedica (LON:OXB) Analyst Target Prices - FTSE News (LON:OXB)
www.ftsenews.co.uk - July 12 at 11:02 AM
ftsenews.co.uk logoOxford Biomedica (LON:OXB) New Price Targets - FTSE News (LON:OXB)
www.ftsenews.co.uk - July 7 at 6:43 PM
fiscalstandard.com logoNew Analyst Ratings For Oxford Biomedica (LON:OXB) - Fiscal Standard (LON:OXB)
www.fiscalstandard.com - June 29 at 6:35 PM
fiscalstandard.com logoOxford Biomedica (LON:OXB) Broker Roundup - Fiscal Standard (LON:OXB)
www.fiscalstandard.com - June 25 at 10:26 AM
iii.co.uk logoFTSE up on resources after Yellen, follows Europe - Interactive Investor (LON:OXB)
www.iii.co.uk - June 7 at 9:26 AM
publicnow.com logoOxford BioMedica Annual General Meeting (LON:OXB)
www.publicnow.com - June 7 at 8:18 AM
publicnow.com logoMolMed and Oxford BioMedica reviewed and expanded the existing license agreements’ framework (LON:OXB)
www.publicnow.com - June 7 at 3:08 AM
publicnow.com logoEstablishment of a New Non-Exclusive LentiVector® Licence with MolMed (LON:OXB)
www.publicnow.com - June 7 at 2:38 AM
publicnow.com logoNew Non-Exclusive LentiVector Licence with MolMed (LON:OXB)
www.publicnow.com - June 7 at 2:18 AM
News IconOxford Biomedica (LON:OXB) Morning Trade Volumes - Share Trading News (LON:OXB)
www.sharetrading.news - June 6 at 10:24 AM
iii.co.uk logoFTSE stable despite OPEC failing to reach new deal - Interactive Investor (LON:OXB)
www.iii.co.uk - June 2 at 7:05 PM
iii.co.uk logoFTSE rebounds after oil price recovery - Interactive Investor (LON:OXB)
www.iii.co.uk - June 2 at 9:42 AM
stockmarketwire.com logoOxford Biomedica enters R&D collaboration - Stock Market Wire (LON:OXB)
www.stockmarketwire.com - June 2 at 9:42 AM
News IconPublic records - Lancaster Eagle Gazette (LON:OXB)
www.lancastereaglegazette.com - June 2 at 9:42 AM
publicnow.com logoR&D Partnership with Green Cross LabCell (LON:OXB)
www.publicnow.com - June 2 at 5:15 AM
publicnow.com logoOxford BioMedica and Green Cross LabCell form a Partnership to Develop Gene-modified NK Cell Therapeutics in cancer (LON:OXB)
www.publicnow.com - June 2 at 5:05 AM
News IconOxford Biomedica (LON:OXB) Broker Price Targets - Share Trading News (LON:OXB)
www.sharetrading.news - May 31 at 1:54 AM
News IconDon't You Remember a Comedy Song? - Oxford American (LON:OXB)
www.oxfordamerican.org - February 26 at 10:45 AM
News IconDigital PCR to assess gene-editing frequencies (GEF-dPCR) mediated by designer nucleases - Nature.com (LON:OXB)
www.nature.com - February 26 at 10:45 AM
biz.yahoo.com logoFull Year 2015 Oxford BioMedica PLC Earnings Release - Before Market Open (LON:OXB)
biz.yahoo.com - February 25 at 7:07 AM
News IconUK Aims at $15B Gene Therapy Industry - Genetic Engineering & Biotechnology News (LON:OXB)
www.genengnews.com - February 13 at 2:24 PM
trustnet.com logoOxford Biomedica PLC (OXB) (LON:OXB)
www.trustnet.com - February 12 at 2:25 PM
News IconAnalyst Coverage Updates - Oxford Biomedica (LON:OXB) - Risers & Fallers (LON:OXB)
www.risersandfallers.com - February 11 at 2:16 PM
stockmarketwire.com logoFTSE zips up as Japan installs negative interest rate - Stock Market Wire (LON:OXB)
www.stockmarketwire.com - January 29 at 12:50 PM
iii.co.uk logoFTSE rising as financials surge on Japan rate call - Interactive Investor (LON:OXB)
www.iii.co.uk - January 29 at 12:50 PM
publicnow.com logoOxford BioMedica Announces Initiation of Second CART Programme for Major Pharmaceutical Company (LON:OXB)
www.publicnow.com - January 29 at 2:04 AM
News IconRecent Broker Updates On Oxford Biomedica (LON:OXB) - Risers & Fallers (LON:OXB)
www.risersandfallers.com - January 27 at 12:16 PM
noodls.com logoOxford BioMedica Announces Successful MHRA Inspection and Approval to Manufacture at its new Facility in Yarnton, Oxford (LON:OXB)
www.noodls.com - January 13 at 2:07 AM
noodls.com logoOxford BioMedica plc (“Oxford BioMedica” or “the Group”) (LSE: OXB), a leading gene and cell therapy group, is pleased to announce that Dr. Lorenzo Tallarigo will be appointed as Non-Executive Chairman of the Group on 1 February 2016. (LON:OXB)
www.noodls.com - December 15 at 2:25 AM
noodls.com logoOxford BioMedica to present at the Jefferies 2015 Global Healthcare Conference, London (LON:OXB)
www.noodls.com - November 18 at 5:59 AM
noodls.com logoGSK Exercises Option on Oxford BioMedica’s LentiVector® Technology Patents (LON:OXB)
www.noodls.com - October 28 at 3:07 AM
noodls.com logoOxford BioMedica to present at JMP Securities Life Sciences Conference 2015 in New York and to attend ROTH Healthcare Day in London (LON:OXB)
www.noodls.com - June 23 at 7:04 AM
noodls.com logoOxford BioMedica to Present at Jefferies 2015 Global Healthcare Conference, New York (LON:OXB)
www.noodls.com - May 29 at 2:24 AM
noodls.com logoOxford BioMedica Appoints Daniel Soland as Non-Executive Director to the Board (LON:OXB)
www.noodls.com - May 13 at 5:27 AM
noodls.com logoOxford BioMedica’s Phase I study results with RetinoStat® were selected as a “Hot Topic” at the Association for Research in Vision and Ophthalmology conference in US (LON:OXB)
www.noodls.com - May 5 at 2:09 AM
noodls.com logoOxford BioMedica announces that a summary of the 12 month and three year follow up data from the Phase I/II study with ProSavin® was presented at the AANS conference in the US (LON:OXB)
www.noodls.com - May 5 at 2:09 AM
noodls.com logoOxford BioMedica secures $50 million loan facility with Oberland Capital to support the Group's growth ambitions (LON:OXB)
www.noodls.com - May 1 at 3:52 AM
noodls.com logoOxford BioMedica 2014 Annual Report and Accounts & AGM Notification (LON:OXB)
www.noodls.com - April 2 at 12:05 PM
noodls.com logoOxford BioMedica to Present at 3rd Annual Regen Med Investor Day (LON:OXB)
www.noodls.com - March 23 at 7:57 AM


Last Updated on 8/25/2016 by MarketBeat.com Staff